

## **Sensimed AG extends oversubscribed Series B funding to CHF 18.6 Million**

**Lausanne, Switzerland**, September 8<sup>th</sup>, 2010 – Sensimed AG, a Swiss company with its principal focus on design, development, and commercialization of integrated micro-systems for medical devices, has closed an extension to its oversubscribed Series B round with an additional CHF 5 million from Agate Medical Investments LP and CHF 3.5 million from New Value AG. The additional funding brings the total Series B financing to CHF 18.6 million, led by Wellington Partners and Vinci Capital/Renaissance PME.

Sensimed has developed the SENSIMED Triggerfish<sup>®</sup>, a revolutionary tool for continuous monitoring of fluctuations in intra-ocular pressure for the management of related diseases such as glaucoma. The tool will not only revolutionize the way glaucoma is diagnosed and treatment is performed, but will also make a contribution to a deeper understanding of its progression. For the first time it will allow ophthalmologists to personalize the patient's treatment and to monitor the efficacy of the treatment.

Says Jean-Marc Wismer, CEO: "We are very happy to complement our shareholders base with new strong institutional investors. The company is strongly financed and in an excellent position to tackle further clinical application trials, regulatory approval in additional geographies, and commercialization efforts."

Michel Habib, Venture Partner at Agate Medical Investments, explains Sensimed's investment merit in Agate's eyes: "We like companies offering meaningful clinical benefit, answering a real unmet need in a large market. Coupled with an attractive business model and a favorable regulatory environment, we believe Sensimed is a potential winner. Sensimed has an excellent chance to be the next game changer in the glaucoma market, with key ingredients, including skilled management and impressive engineering execution that would enable capitalizing on its innovation and build substantial value to its shareholders."

Peter Letter, head of investment management at New Value, emphasizes the excellent accordance of the investment in Sensimed with New Value's sustainable investment approach: "SENSIMED Triggerfish<sup>®</sup> fulfills an urgent unmet medical need without harming the patient and can contribute to prevent patients from going blind. This does not only reduce the burden to the social security systems, but also helps to maintain the quality of life of people affected by glaucoma. Sensimed is an excellent example how leading-edge Swiss technology does address a worldwide market potential."

Further information about Sensimed AG is available on [www.sensimed.ch](http://www.sensimed.ch)

### About Agate Medical Investments

Agate Medical Investments LP is a unique venture capital fund, which invests in Israeli and international medical device companies and in healthcare services. The \$65M fund, based in Tel Aviv, manages since its inception in September 2007 eight portfolio companies, targeting investments in mid to late stage companies. Agate was established by Dani Naveh, former Israeli Minister of Health and Cabinet Secretary, with the endorsement of leading financial institutions and private investors. The fund is managed by prominent and highly-experienced partners with extensive knowledge and track record in the Medtech industry and access to decision-makers worldwide. For further information please visit [www.agate-invest.com](http://www.agate-invest.com).

### About New Value AG

New Value, listed at the SIX Swiss Exchange, invests directly in promising private companies in Switzerland and neighbouring countries with above-average market and growth potential. As an investment company, New Value promotes innovative business models with venture capital and accompanies those to market success. The portfolio covers companies of different stages of development, starting with the market introduction phase up to medium-sized enterprises with stable profits. A broad investment approach is deliberately followed regarding industry sectors. The portfolio contains companies active in cleantech and healthcare. New Value assigns great value to ethical business concepts and good corporate governance while selecting their portfolio companies. Criteria such as meaningfulness, social responsibility and ecological sustainability are considered by New Value as decisive competitive advantages, which affect and enhance the quality of products and services offered and thus, facilitate an above average increase of value potential. Since the formation of New Value, EPS Value Plus AG, Zurich, has served as investment manager. For further information please visit [www.newvalue.ch](http://www.newvalue.ch).

#### *Contact details:*

**SENSIMED AG**

*Jean-Marc Wismer, CEO*

*Tel. +41 78 636-2951*

*Email: [jean-marc\\_wismer@sensimed.ch](mailto:jean-marc_wismer@sensimed.ch)*

SENSIMED AG

Rue Centrale 6 • 1003 Lausanne • Switzerland

Tel. +41 21 311 9025 • Fax. +41 21 311 9027

[www.sensimed.ch](http://www.sensimed.ch) • [info@sensimed.ch](mailto:info@sensimed.ch)